Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(80 intermediate revisions by 5 users not shown)
Line 1: Line 1:
Welcome! 


*For assignments, please see the "Author" column below.  If no name is present, volunteer to create content!
*We will be creating content for all entities with genetic findings in the current WHO Classification of Tumours books.  If there is an entity not yet listed below that you would like to author, we would be happy to create a page for you now.
*To volunteer, please '''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your page of interest.
__TOC__
==WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content==
{| class="wikitable"
{| class="wikitable"
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Disease'''!!'''Page Type'''!!'''Author'''
Line 23: Line 17:
|
|
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
|Date page was created
|
|
|
|-
|-
Line 33: Line 27:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 43: Line 37:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 67: Line 61:
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|complete
|complete/pending faculty review
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Chelsea D. Kramish (trainee), Daynna J.Wolff
|(trainee), Daynna J.Wolff
|
|
|
|
|complete/pending faculty review
|pending faculty review
|
|
|FQR
|FQR
Line 88: Line 82:
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Thomas Lee
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|complete
|complete
|
|
Line 96: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
Line 105: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung + Shuo-Shawn Liu (trainee)
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|complete
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Systemic Mastocytosis||Disease
|    Systemic Mastocytosis||Disease
Line 125: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung +Jordan Lowery (trainee)
|Thuy Phung +Jordan Lowery
|
|
|
|
Line 181: Line 175:
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
|
|
|
|
Line 192: Line 186:
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee) + Daynna J. Wolff
|
|
|
|
Line 231: Line 225:
|
|
|9/1/20
|9/1/20
|PENDING importing content and reference formatting
|PENDING
|
|
|FQR
|FQR
|
|
|FQR has emailed SR several times, last 4/20/22
|
|-
|-
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
Line 243: Line 237:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 255: Line 249:
|
|
|-
|-
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Jack Reid (trainee)+Fabiola Quintero-Rivera
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|
|
|4/21/22
|9/1/20
|pending
|pending
|
|
Line 293: Line 287:
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 303: Line 297:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 330: Line 324:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 474: Line 468:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)
Corboy (Monash Health)
|
|
|
|
Line 483: Line 476:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 491: Line 484:
|Add WHO reference
|Add WHO reference
|-
|-
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Corboy (Monash Health)
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Conboy (Monash Health)
|
|
|
|
Line 709: Line 702:
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
|Disease
|Disease
|Kay Weng Choy + Greg Corboy (Monash Health)
|Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 764: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
Line 836: Line 829:
|
|
|
|
|Complete
|PENDING
| ||YA
| ||YA
|
|
Line 929: Line 922:
| ||YA
| ||YA
|
|
|2021 template added
|
|-
|-
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
Line 937: Line 930:
| ||YA
| ||YA
|
|
|2021 template added
|
|-
|-
| || ||
| || ||
Line 955: Line 948:
|
|
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Jamie Nagy
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 964: Line 957:
|
|
|-
|-
|       Monoclonal B-cell  Lymphocytosis||Disease||Jamie Nagy
|       Monoclonal B-cell  Lymphocytosis||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 1,034: Line 1,027:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|   Waldenstrom  Macroglobulinemia||Disease||
|   Waldenstrom  Macroglobulinemia||Disease||
Line 1,043: Line 1,036:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
Line 1,061: Line 1,054:
|
|
|-
|-
|    Mu Heavy Chain  Disease||Disease||Manisha Sutariya
|    Mu Heavy Chain  Disease||Disease||
|
|
|
|
Line 1,130: Line 1,123:
|
|
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
|           Primary  Amyloidosis||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|           Light Chain  and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|8/31/2021
|
|9/15/2021
|
|PENDING
|
| ||SP
| ||SP
|
|
|
|
|-
|-
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
|         POEMS Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
|         TEMPI Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|3/9/21
|3/9/21
|
|
Line 1,185: Line 1,178:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
Line 1,274: Line 1,267:
|
|
|-
|-
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Mahsa Khanlari, MD
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||
|
|
|
|
|
|?PENDING
|
|
|SP
|SP
Line 1,307: Line 1,300:
|Greg Corboy (GC)
|Greg Corboy (GC)
|
|
|Requested to update 14022022
|
|-
|-
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
Line 1,317: Line 1,310:
|
|
|-
|-
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|26/10/2021
|
|26/1/2022
|
|Complete
|
|03/28/22||GC
| ||GC
|03/28/22
|
|2021 template added
|
|-
|-
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
Line 1,381: Line 1,374:
|
|
|-
|-
|Intravascular Large B-cell Lymphoma||Disease||Kate Berry, Greg Corboy
|Intravascular Large B-cell Lymphoma||Disease||
|25/01/2022
|
|25/4/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|ALK-Positive Large B-cell Lymphoma||Disease||
|ALK-Positive Large B-cell Lymphoma||Disease||
Line 1,395: Line 1,388:
| ||GC
| ||GC
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y
|
|-
|-
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
Line 1,402: Line 1,395:
|Complete
|Complete
| ||GC
| ||GC
|28/03/2022
|
|
|
|-
|-
Line 1,421: Line 1,414:
|
|
|-
|-
|   Multicentric Castleman  Disease||Disease||Sudha Arumugam
|   Multicentric Castleman  Disease||Disease||
|10/26/2021
|
|1/26/2022
|
|Complete
|
|24/01/2022||GC
|24/01/2022
|2021 template added
|-
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sudha Arumugam
|10/26/2021
|1/26/2022
|PENDING
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||Sudha Arumugam
|   HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|-
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|3/11/21
|06/28/2021
|Complete
|28/06/2021||GC
|28/06/2021
|
|
|-
|-
|Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
|10/13/21
|01/13/2022
|Complete
|27/01/2022
|GC
|27/01/2021
|2021 template added
|-
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|
|
|
|
Line 1,470: Line 1,438:
|
|
|-
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|30/05/21
|3/11/21
|30/08/21
|
|Complete
|PENDING
|24/02/2022||GC
| ||GC
|24/02/2022
|
|
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
|7/30/21
|10/30/21
|Complete
|15/11/2021
|GC
|16/11/2021
|
|
|-
|-
|B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
|
|
|
|
Line 1,495: Line 1,454:
|
|
|-
|-
| || ||
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|
|
|
|
|
|
| ||
| ||GC
|
|
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
|
|
|
| ||GC
|
|
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
|
|
|
| ||GC
|
|
|-
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|
|
|
| ||GC
|
|
|-
| || ||
|
|
|
| ||
|
|
|
|
Line 1,535: Line 1,526:
|
|
|-
|-
|Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|Aggressive NK-cell Leukemia||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,554: Line 1,545:
|
|
|
|
|Complete
|PENDING
|11/21/2021||SP
| ||SP
|
|
|
|
Line 1,567: Line 1,558:
|
|
|-
|-
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|
|
|
|
Line 1,583: Line 1,574:
|
|
|-
|-
|Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
|Adult T-cell Leukemia/Lymphoma||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,677: Line 1,668:
|
|
|-
|-
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Lymphomatoid  Papulosis||Disease||Peining Li, PhD
|    Lymphomatoid  Papulosis||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,842: Line 1,833:
|
|
|-
|-
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||Xiaolin (Lynn) Hu
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|Completed
|03/21/22||GC
|03/21/22
|Edits sent 14022022
|-
|    Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|
|
| ||GC
|
|
|PENDING
| ||GC
|
|
|2021 template added
|-
|-
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|    Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
Line 1,882: Line 1,865:
|
|
|-
|-
|Lymphomas Associated with HIV Infection||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|11/2/21
|
|02/02/22
|
|Completed
|
|03/21/22
| ||GC
|GC
|
|03/21/22
|
|-
|Lymphomas Associated with HIV Infection||Disease||
|
|
|
| ||GC
|
|
|
|-
|-
Line 1,907: Line 1,897:
|
|
|-
|-
|    Polymorphic  Post-Transplant Lymphoproliferative Disorders||Disease||Ania Shestakova (trainee) + Fabiola Quintero-Rivera
|    Polymorphic  Post-Transplant Lymphoproliferative Disorders||Disease||Anna Shestakova (trainee)''+,''
 
Fabiola Quintero-Rivera
|
|
|
|
|completed
|PENDING
|april 2022
|
|GC
|GC
|
|
Line 1,964: Line 1,956:
|
|
|-
|-
|Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
|Histiocytic Sarcoma||Disease||
|
|
|
| ||GC
|
|
|
|
|Complete
|10/01/2021
|GC
|10/01/2021
|Xinjie Xu
|-
|-
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
Line 1,981: Line 1,972:
|
|
|-
|-
|   Langerhans Cell  Histiocytosis||Disease||Malaika Perchard, Greg Corboy
|   Langerhans Cell  Histiocytosis||Disease||
|02/01/2022
|
|05/01/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|emailed 28/3/2022 to get update
|-
|   Langerhans Cell  Sarcoma||Disease||Malaika Perchard, Greg Corboy
|02/01/2022
|05/01/2022
|PENDING
| ||GC
|
|
|emailed 28/3/2022 to get update
|-
|-
|Indeterminate Dendritic Cell Tumour||Disease||
|   Langerhans Cell  Sarcoma||Disease||
|
|
|
| ||GC
|
|
|-
|Indeterminate Dendritic Cell Tumour||Disease||
|
|
|
|
Line 2,045: Line 2,036:
|
|
|-
|-
|Erdheim-Chester Disease||Disease||Prashant Deshpande
|Erdheim-Chester Disease||Disease||
|02/02/2022
|05/02/2022
|PENDING
| ||GC
|
|emailed 28/3/2022 to get update
|-
| || ||
|
|
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 2,212: Line 2,195:
|
|
|
|
|}<br />
==WHO Classification of Tumours of the Central Nervous System Content==
{| class="wikitable"
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
| || ||
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|Medulloblastoma, WNT-activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|
|
|PENDING
|
|
|Holli Drendel (interim)
|
|
|2021 template added
| ||
|-
|Paediatric-Type Diffuse High-Grade Gliomas
|Overview
|
|
|
|
|
|}
|
|
|
|
|2021 template added
|-
|Diffuse Midline Glioma, H3 K27-Altered
|Disease
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|
|
|
|
|
|
|2021 template added
|-
|Diffuse Hemispheric Glioma, H3 G34-Mutant
|Disease
|Xiaolin (Lynn) Hu
|2/21/2022
|
|PENDING
|
|PENDING (Laveniya?)
|
|2021 template added
|-
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype
|Disease
|
|
|
|
|
|
|
|2021 template added
|-
|Infant-Type Hemispheric Glioma
|Disease
|
|
|
|
|
|
|
|2021 template added
|-
|Astrocytoma, IDH-Mutant
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|PENDING
|
|
|
|2021 template added
|-
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|PENDING
|
|
|
|2021 template added
|-
|}<br />
 
==WHO Classification of Soft Tissue and Bone Tumours Content==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|NTRK-Rearranged Spindle Cell Neoplasm||Disease||James Solomon, MD, PhD
|2/20/2022
|
|PENDING
|
|Alanna Church
|
|
|-
|}<br />
 
==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)==
{| class="wikitable sortable"
{| class="wikitable sortable"
|+Gene-Specific Pages
!'''Gene'''
!'''Gene'''
!'''Author'''
!'''Author'''
Retrieved from "https://content.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"